All In Biotech

Drug Trial Radar · NCT05364944

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

A Phase 1b Study in Patients With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) to Characterize the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Debio 4126, a 12-week Prolonged-release Octreotide Formulation

Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

19

Actual

Start

May 18, 2022

Primary completion

Oct 29, 2024

Study completion Dec 3, 2024

Sponsor

Lead sponsor
Debiopharm International SAIndustry
Sponsor type
Industry
First posted
May 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single treatment arm, multicenter study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of Debio 4126 in the treatment of participants with Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine tumors (GEP-NETs).

Conditions

  • Acromegaly
  • GEP-NET

Interventions

  • Debio 4126Drug

    Intramuscular (IM) injection

  • Sandostatin LARDrug

    Sandostatin LAR will be administered as IM injection as pre-study treatment dose prior to Debio 4126 administration

  • Somatuline ATGDrug

    Somatulin ATG will be administered as deep subcutaneous (SC) injection as pre-study treatment dose prior to Debio 4126 administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma Concentration of Debio 4126 in Acromegaly and GEP-NET ParticipantsTime frame: Predose at Days -28 to -7; Postdose at multiple timepoints from Day 1 to Day 337

Locations

14 sites in 8 countries. Site status is shown where the registry gives one.

  • Rigshospitalet, Endokrinologisk afdeling

    Copenhagen, Denmark

  • CHU Angers

    Angers, France

  • AP-HP Hopital Bicetre

    Le Kremlin-Bicêtre, France

  • AP-HM - Hôpital de la Conception, Service d'Endocrinologie et Centre de Référence des Maladies Rares de l'hypophyse

    Marseille, France

  • Medicover Praxis fur Neuroendokrinologie

    Munich, Germany

  • Rabin Medical Center, Beilinson Hospital, Clalit Health Services by Rabin Medical Center, Beilinson Hospita

    Petah Tikva, Israel

  • Sheba Medical Center, Endocrine institute

    Ramat Gan, Israel

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano

    Milan, Italy

  • Uniwersyteckie Centrum Kliniczne im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego w Katowicach

    Katowice, Poland

  • Mazowiecki Szpital Brodnowski - Zespol Oddzialow Chorob Wewnetrznych, Endokrynologii i Diabetologii

    Warsaw, Poland

  • Hospital de la Santa Creu i Sant Pau Barcelon

    Barcelona, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • University Hospital Coventry, WISDEM Centre, UHCW NHS Trust

    Coventry, United Kingdom

  • Royal Free London NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.